New progress in endoscopic treatment of esophageal diseases

Ping-Hong Zhou, Qiang Shi, Yun-Shi Zhong, Li-Qing Yao

Endoscopy Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Author contributions: Zhou PH, Shi Q and Zhong YS contributed equally to this paper; Zhou PH designed the research; Shi Q and Zhong YS analyzed and interpreted the data, and drafted the article; Yao LQ provided final approval of the article.

Supported by National Natural Science Funds of China, No. 81101566; and Scientific Funds of Shanghai Government, 11DZ2280400, 12QA1400600, XYQ2011017, 11411950500

Correspondence to: Li-Qing Yao, MD, Endoscopy Center, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China. yaoliqingfd@126.com

Received: August 14, 2013
Revised: September 11, 2013
Accepted: September 29, 2013
Published online: November 7, 2013

Abstract

The technique of endoscopic submucosal dissection (ESD), which was developed for "en bloc" resection of large lesions in the stomach, has been widely accepted for the treatment of the entire gastrointestinal tract. Many minimally invasive endoscopic therapies based on ESD have been developed recently. Endoscopic submucosal excavation, submucosal tunneling endoscopic resection and laparoscopic-endoscopic cooperative surgery have been used to remove submucosal tumors, especially tumors which originate from the muscularis propria of the digestive tract. Peroral endoscopic myotomy has recently been described as a scarless and less invasive surgical myotomy option for the treatment of achalasia. Patients benefit from minimally invasive endoscopic therapy. This article, in the highlight topic series, provides detailed information on the indications and treatments for esophageal diseases.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

INTRODUCTION

Endoscopic submucosal dissection (ESD) was originally developed in Japan as a method of "en bloc" resection of superficial gastric cancers. Today, ESD is increasingly used for superficial esophageal cancers and esophageal submucosal tumors (SMTs). With improved ESD technology, it has been used not only for tumors, but also for functional disorders, and has produced good therapeutic effects. In this review, an outline of the current status of minimally invasive endoscopic therapy based on ESD for esophageal diseases is described.

ESD

As with candidates suffering from other gastrointestinal tract diseases, patients scheduled for esophageal ESD are assessed using two factors: a small likelihood of lymph node metastasis and technical resectability. ESD for lesions in esophageal squamous epithelium is performed as outlined in Figure 1. The lesion is dyed with 2% Lugol's solution to obtain a clear margin, and
several marker dots are made approximately 5-10 mm from the margin of the lesion using argon plasma coagulation (APC). After injection of several milliliters of injection solution into the submucosal layer, the mucosa is incised outside the marker dots with an electric knife (IT knife, hook knife, or HybridKnife). The submucosal tissue underneath the lesion is then gradually dissected with the electric knife. The solution is injected repeatedly, when necessary, during the dissection. Exposed vessels on the artificial ulcer are coagulated with APC or coagulation forceps to prevent delayed bleeding, and metallic clips are always used to close the deeply dissected areas. Although numerous injection solutions have been proposed and tested, saline is the most commonly used in the clinic due to its low cost and ease of use. Indigo carmine is added to obtain a clear layer and epinephrine is used to reduce bleeding. Hyaluronic acid is also used to improve submucosal lift durations\[5-7\].

**ENDOSCOPIC SUBMUCOSAL EXCAVATION**

With improved ESD technology, ESD is not only used for mucous layer tumors, but also for muscularis propria tumors of the digestive tract. During this process, ESD is used to remove the submucosa muscularis propria of the tumor and to peel the tumor from the muscularis propria. We consider this application a new technology and named it endoscopic submucosal excavation (ESE). ESE is performed as outlined in Figure 2: (1) Marker dots are made approximately 5 mm away from the lesion; (2) Using a 23-gauge disposable needle, several milliliters of submucosal injection solution are injected around the lesion to lift it off the muscularis propria layer, but only the mucosa is lifted, not the tumor. This step shows that the tumor has originated from the muscularis propria layer; (3) The mucosa is then incised outside the marker dots using the electric knife; (4) The submucosal connective tissue beneath the lesion is gradually dissected from the muscularis propria layer with the electric knife to show the lesion; and (5) The electric knife is used to peel the muscularis propria layer along the edge of the lesion. Finally, the lesion is resected completely from the muscularis propria layer using the electric knife\[8,9\].

**SUBMUCOSAL TUNNELING ENDOSCOPIC RESECTION**

ESE was developed to allow en bloc resection of SMTs which originated from the muscularis propria layer under direct vision. However, the surgical area in the esophagus is limited and the esophageal adventitia is very thin. If perforation occurs and the mucosal defect cannot be completely closed, serious complications such as esophageal fistula will occur. We performed a new endoscopic technique for the treatment of SMTs, called submucosal tunneling endoscopic resection (STER), which can reduce the risk of postoperative GI tract leakage and secondary infection. The procedure for STER is as follows: (1) Submucosal injection of diluted indigo carmine or methylene

---

**Figure 1** Process of endoscopic submucosal dissection. A: The lesion is dyed with 2% Lugol’s solution; B: Marking of the lesion by argon plasma coagulation probes; C: Submucosal injection; D: The mucosa is incised outside the marker dots, and then the submucosal tissue underneath the lesion is gradually dissected; E: The wound after resection; F: The lesion.
blue is needed to locate SMTs in the cardia when they are difficult to identify; (2) A submucosal tunnel is created to expose the tumor. A fluid cushion is obtained using an injection needle 5 cm proximal to the SMT. A 2-cm, longitudinal mucosal incision is made using the electric knife at the esophageal mucosa as the entry point. A submucosal longitudinal tunnel is created with the electric knife between the submucosal and muscular layers. Tunneling
ends 1-2 cm distal to the tumor to ensure a satisfactory endoscopic view of the SMT and enough working space for resection; (3) Resection of the SMT is performed under direct endoscopic visualization. During the procedure, safe and complete resection of the tumor, without interruption of the tumor capsule, is the highest priority; and (4) Closure of the mucosal incision site. After tumor resection and hemostasis with APC or hot biopsy forceps in the tunnel, the gastroscope is withdrawn through the natural orifice. Most commonly, the mucosal incision site is closed with 4 to 6 hemostatic clips\textsuperscript{(10)} (Figure 3).
Peroral endoscopic myotomy has recently been described as a scarless and less invasive surgical myotomy option for the treatment of achalasia. Briefly, submucosal injection and an initial mucosal incision are first performed at the 5- to 6-o’clock position on the posterior esophagus, approximately 10 cm proximal to the esophagogastric junction.

Figure 5 Process of thoracoscope-assisted tunnel endoscopic resection. A: Thoracoscopic exploration of the tumor; B: Endoscopic exploration of the tumor; C-D: A submucosal tunnel was created to expose the tumor under endoscopy, which was the same as the submucosal tunneling endoscopic resection procedure; E: The thoracoscopic electric hook was used to separate the esophagus and open the muscular layer over the tumor by blunt dissection, we removed the large tumor from the chest; F: Use of metallic clips to close the mucosal entry; G: Use of thoracoscopy to suture the pleura mediastinalis; H: The lesions.
junction (EGJ). A submucosal tunnel is created passing over the EGJ and approximately 3 cm into the proximal stomach. The myotomy is initiated 2 cm distal to the mucosal entry point, approximately 6-8 cm above the EGJ, and is extended for a distance of 2-3 cm toward the stomach. After careful hemostasis, the mucosal incision site is closed with 4 to 6 hemostatic clips[14-16] (Figure 4).

**THORACOSCOPE-ASSISTED TUNNEL ENDOSCOPIC RESECTION**

With the development of ESD technology, endoscopy is used to treat large esophageal SMTs. Thus, endoscopic treatment is risky and of limited value in patients with huge esophageal or extraluminal SMTs. Minimally invasive thoracoscopic treatment also has its advantages, however, for esophageal SMTs larger than 3 cm, use of the thoracoscope involves a risk of tearing the mucosa when separating tumors, causing serious complications such as GI leakage. Laparoscopic-endoscopic cooperative surgery has been introduced[17,18]. Recently, we developed combined thoroscopic and endoscopic therapy to treat esophageal SMTs originating from the muscularis propria. The indications for thoracoscope-assisted tunnel endoscopic resection are: (1) Tumors larger than 5 cm; and (2) U-shaped tumors larger than 3 cm and which extend to more than 1/2 of the esophagus circumference. This type of tumor is difficult to treat by endoscopic or thoracoscopic treatment alone. The detailed steps of this procedure are as follows: The patient lies in the left lateral position, the thoracoscope is introduced and any adhesion or pleural effusion in the pleural cavity is checked; (1) Thoracoscopic exploration of the tumor; (2) Submucosal injection is administered and a submucosal tunnel is created to expose the tumor using the ESD technique under endoscopy, which is the same as the STER procedure; (3) If the tumor is so large that it cannot be removed from the tunnel by endoscopy, the thoracoscopic electric hook is used to separate the esophagus and open the muscular layer over the tumor by blunt dissection. In addition, the submucosal “tunnel” is under surveillance by endoscopy to avoid esophageal mucosa injury; (4) Under endoscopic surveillance in the submucosal tunnel, the esophageal muscular layer is sutured by thoracoscopic and insufflation in the tunnel is performed to observe whether there is any leakage in the thoracic cavity. The endoscope is withdrawn from the submucosal tunnel after hemothorax and metallic clips are used to close the mucosal entry; (5) Endoscopy is used to identify mucosal rupture. The esophagus is insufflated to observe any leakage in the thoracic cavity and then thoracoscopic is used to suture the pleura mediastinalis; and (6) A drainage tube is placed in the chest cavity if there is no obvious bleeding[19] (Figure 5).

The main complications consist of bleeding, perforation and esophageal stricture, most of which were treated by endoscopy and surgery was not required[20,22]. With the development of endoscopic techniques and the improvement in people’s health consciousness, the model of the diagnosis and treatment of some esophageal diseases is changing. Patients benefit from minimally invasive endoscopic therapy based on ESD, which results in reduced pain, rapid resumption of normal activity, and shorter hospital stay.

**REFERENCES**

1. Cai MY, Zhou PH, Yao LQ. Current status of endoscopic resection in China. *Dig Endosc* 2012; 24 Suppl 1: 166-171 [PMID: 22533775 DOI: 10.1111/den.12026.x]
2. Honda K, Akiho H. Endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. *World J Gastrointest Pathophysiol* 2012; 3: 44-50 [PMID: 22532931 DOI: 10.4251/wjg.v3.i2.44]
3. Ono S, Fujishiro M, Koike K. Endoscopic submucosal dissection for superficial esophageal neoplasms. *World J Gastrointest Endosc* 2012; 4: 162-166 [PMID: 22624067 DOI: 10.4253/wjge.v4.i5.162]
4. Yamashina T, Ishihara R, Uedo N, Nagai K, Matsui F, Kawada N, Oota T, Kanzaki H, Hanafusa M, Yamamoto S, Hanaoa N, Takeuchi Y, Higashino K, Ishii H. Safety and curative ability of endoscopic submucosal dissection for superficial esophageal cancers at least 50 mm in diameter. *Dig Endosc* 2012; 24: 220-225 [PMID: 22725105 DOI: 10.1111/j.1443-1661.2011.01215.x]
5. Hashimoto S, Kobayashi M, Takeuchi M, Sato Y, Narisawa R, Aoyagi Y. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. *Gastroint Endosc* 2011; 74: 1389-1393 [PMID: 22136782 DOI: 10.1016/j.gie.2011.07.070]
6. Tran RT, Palmer M, Tang SJ, Abell TL, Yang J. Injectable drug-eluting elastomeric polymer: a novel submucosal injection material. *Gastroint Endosc* 2012; 75: 1092-1097 [PMID: 22301346 DOI: 10.1016/j.gie.2011.12.009]
7. Kantele VO, Adler DG, Conway JD, Diehl DL, Farraye FA, Kwon R, Mamula P, Rodriguez S, Shah RJ, Wong Kee Song LM, Tierney WM. Endoscopic mucosal resection and endoscopic submucosal dissection. *Gastroint Endosc* 2008; 68: 11-18 [PMID: 18577472 DOI: 10.1016/j.gie.2008.01.037]
8. Li QL, Yao LQ, Zhou PH, Xu MD, Chen SY, Zhong YS, Zhang YQ, Chen WF, Ma LL, Qin WZ. Submucosal tumors of the esophagogastric junction originating from the muscularis propria layer; a large study of endoscopic submucosal dissection with video). *Gastroint Endosc* 2012; 75: 1153-1158 [PMID: 22459663 DOI: 10.1016/j.gie.2012.01.037]
9. Shi Q, Zhong YS, Yao LQ, Zhou PH, Xu MD, Wang P. Endoscopic submucosal dissection for treatment of esophageal submucosal tumors originating from the muscularis propria layer. *Gastroint Endosc* 2011; 74: 1194-1200 [PMID: 21963065 DOI: 10.1016/j.gie.2011.07.039]
10. Xu MD, Cai MY, Zhou PH, Qin XY, Zhong YS, Chen WF, Hu JW, Zhang YQ, Ma LL, Qin WZ, Yao LQ. Submucosal tunneling endoscopic resection: a new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with video). *Gastroint Endosc* 2012; 75: 195-199 [PMID: 22056807 DOI: 10.1016/j.gie.2011.08.018]
11. Liu BR, Song JT, Kong LJ, Pei FH, Wang XH, Du YJ. Tunneling endoscopic muscularis dissection for subepithelial tumors originating from the muscularis propria of the esophagus and gastric cardia. *Surg Endosc* 2013; 27: 4354-4359 [PMID: 23765425]
12. Inoue H, Tianle KM, Ikeda H, Hosoya T, Onimaru M, Yoshida A, Minami H, Kudo SE. Peroral endoscopic myotomy for esophageal achalasia: technique, indication, and outcomes. *Thorac Surg Clin* 2011; 21: 519-525 [PMID: 22040634 DOI: 10.1016/j.thorsurg.2011.08.005]
13. Von Renteln D, Fuchs KH, Fockens P, Bauerfeind P, Vas-
siliou MC, Werner YB, Fried G, Breithaupt W, Heinrich H, Bredenoord AJ, Kersten JF, Verlaan T, Trevisonno M, Rösch T. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. Gastroenterology 2013; 145: 309-11.e1-3 [PMID: 23665071 DOI: 10.1053/j.gastro.2013.04.057]

14 Li QL, Chen WF, Zhou PH, Yao LQ, Xu MD, Hu JW, Cai MY, Zhang YQ, Qin WZ, Ren Z. Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. J Am Coll Surg 2013; 217: 442-451 [PMID: 23891074 DOI: 10.1016/j.jamcollsurg.2013.04.033]

15 Li QL, Zhou PH, Xu MD, Cai MY, Yao LQ. Offshoots of peroral endoscopic myotomy: Submucosal tunneling endoscopic resection, pyloromyotomy, and beyond. Tech Gastroint Endosc 2013; 15: 160-163

16 Zhou PH, Li QL, Yao LQ, Xu MD, Chen WF, Cai MY, Hu JW, Li L, Zhang YQ, Zhong YS, Ma LL, Qin WZ, Cui Z. Peroral endoscopic remyotomy for failed Heller myotomy: a prospective single-center study. Endoscopy 2013; 45: 161-166 [PMID: 23389963 DOI: 10.1055/s-0032-1326203]

17 Shi Q, Xu MD, Zhong YS, Zhou PH, Wu HF, Yao LQ. The laparoscopic-endoscopic cooperative surgery for the colonic calcifying fibrous tumor: one case report. J Laparoscend Adv Surg Tech A 2012; 22: 996-998 [PMID: 23072410 DOI: 10.1089/lap.2012.0288]

18 Zhang YQ, Lu W, Yao LQ, Qin XY, Xu MD, Zhong YS, Li QL, Wu HF, Zhou PH. Laparoscopic direct suture of perforation after diagnostic colonoscopy. Int J Colorectal Dis 2013; 28: 1505-1509 [PMID: 23881466]

19 Zhong YS, Shi Q, Guo WG, Ren Z, Chen T, Yao LQ. Thoracoscope assisted tunnel endoscopic resection for esophageal SMT from the muscularis propria. Zhonghua Weichang Waike Zazhi 2012; 15: 404-405 [DOI: 10.3760/cma.j.issn.1671-0274.2012.04.027]

20 Sato H, Inoue H, Ikeda H, Grace R Santi E, Yoshida A, Onimaru M, Kudo S. Clinical experience of esophageal perforation occurring with endoscopic submucosal dissection. Dis Esophasus 2013; Aug 27; Epub ahead of print [PMID: 23980646 DOI: 10.1111/dote.12125]

21 Li QL, Zhou PH, Yao LQ, Xu MD, Chen WF, Hu JW, Cai MY, Zhang YQ, Zhong YS, Qin WZ, He MJ. Early diagnosis and management of delayed bleeding in the submucosal tunnel after peroral endoscopic myotomy for achalasia (with video). Gastrointest Endosc 2013; 78: 370-374 [PMID: 23680177 DOI: 10.1016/j.gie.2013.04.172]

22 Ohki T, Yamato M, Ota M, Takagi R, Murakami D, Kondo M, Sasaki H, Namiki H, Okano T, Yamamoto M. Prevention of esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. Gastroenterology 2012; 143: 582-8.e1-582-8.e2 [PMID: 22561054 DOI: 10.1053/j.gastro.2012.04.050]

P- Reviewers: Ciaccio EJ, Kobayashi N, Toyokawa T
S- Editor: Qi Y    L- Editor: Webster JR    E- Editor: Ma S
